Albumin replacement therapy in immunocompromised patients with sepsis - Secondary analysis of the ALBIOS trial.

Background: The best fluid replacement strategy and the role of albumin in immunocompromised patients with sepsis is unclear.

Methods: We performed a secondary analysis of immunocompromised patients enrolled in the ALBIOS trial which randomized patients with severe sepsis or septic shock to receive either 20% albumin (target 30 g per liter or more) and crystalloid or crystalloid alone during ICU stay.

Results: Of 1818 patients originally enrolled, 304 (16.

May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department?

Background: Thrombopoietin (TPO), a growth factor primarily involved in regulating thrombopoiesis, has been recently implicated in the pathogenesis of sepsis. TPO levels are, indeed, greatly increased in patients with sepsis compared to control subjects, and correlate with sepsis severity. The aim of this study was to evaluate TPO as predictive biomarker of sepsis and of sepsis severity in patients entering the emergency department (ED) with systemic inflammatory response syndrome (SIRS).

Bleeding prevalence and transfusion requirement in patients with thrombocytopenia in the emergency department.

Background: Thrombocytopenia is the most common coagulation disorder in critically ill patients. No studies have investigated the epidemiology and clinical impact of this condition in emergency department (ED) patients. We aimed to investigate epidemiological features, incidence of bleeding, and diagnostic and therapeutic requirements of patients with thrombocytopenia admitted to the ED.